Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kamaldeen Aderibigbe

Orthopaedic Trauma Des Moines, IA Medical Doctor

NPI 1043454978 CMS profile 734979

450 Laurel St Ste A, Des Moines, IA 50314

Open in the dashboard

General payments

$30,661

147 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kamaldeen Aderibigbe of Des Moines, IA is reported in the CMS Open Payments database as having received $30,661 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,839 20
2024 General $3,333 17
2023 General $2,644 12
2022 General $4,887 23
2021 General $11,317 31
2020 General $1,834 19
2019 General $3,808 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kamaldeen Aderibigbe
  • Orthopaedic Trauma median
  • Middle half of Orthopaedic Trauma
  • National median

In program year 2025, general payments to Kamaldeen Aderibigbe were reported at $2,839. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.

Show as a table
Year Kamaldeen Aderibigbe Orthopaedic Trauma median Middle half National median
2019 $3,808 $1,475 $264–$6,401 $163
2020 $1,834 $596 $120–$4,020 $114
2021 $11,317 $919 $171–$4,697 $132
2022 $4,887 $1,547 $272–$7,240 $149
2023 $2,644 $1,330 $247–$5,875 $160
2024 $3,333 $1,288 $277–$6,797 $164
2025 $2,839 $1,227 $259–$7,433 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $8,140 19 payments
  2. Synthes USA Products LLC $6,561 9 payments
  3. Stryker Corporation $5,239 48 payments
  4. SI-BONE, Inc. $4,521 14 payments
  5. Smith+Nephew, Inc. $2,375 13 payments
  6. DePuy Synthes Sales Inc. $2,375 27 payments
  7. Zimmer Biomet Holdings, Inc. $1,133 13 payments
  8. Globus Medical, Inc. $287 2 payments
  9. Biocomposites Inc $29 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $11,832 9 payments
  2. Travel and Lodging $11,461 32 payments
  3. Food and Beverage $7,367 106 payments
Products named General payments · program years 2019–2025
  1. NA $5,430 2 payments
  2. IFUSE IMPLANT $2,735 9 payments
  3. VA-LCP $2,561 9 payments
  4. MAKO $2,216 12 payments
  5. LCP $1,964 4 payments
  6. MATRIXRIB $1,415 7 payments
  7. IFUSE IMPLANT SYSTEM $1,312 2 payments
  8. PRO $1,154 3 payments
  9. Taylor Spatial Frame $1,110 6 payments
  10. EVOS $1,012 5 payments
  11. Other $8,684 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

139

Median for Orthopedic Surgery: 203

Drug cost

$842

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 92 $476
Oxycodone Hcl Generic 20 $151
Clindamycin Hcl Generic 16 $118
Pregabalin Generic 11 $97

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 117 billing codes

Paid by Medicare

$260,176

Of which drugs: $145

Medicare patients

453

Average age 76

Services billed

3,015

299 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 66%
Depression 31%
Osteoporosis 28%
Diabetes 25%
Ischemic heart disease 25%
Chronic kidney disease 25%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 19 1,360 $137

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Trauma in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record